Novel Fully Human Antibody Development Group Joins Top Synthetic Biology Company

BLACKSBURG, VA, Oct 24, 2011 (MARKETWIRE via COMTEX) -- Intrexon Corporation, a privately held synthetic biology company, today announced the acquisition of Immunologix, Inc., of Charleston, SC. Immunologix specializes in transforming naive B-cells to produce 100% human monoclonal antibodies that can target all antigen types including, but not limited to cancer cells, viruses, bacteria, toxins, plus those epitopes related to autoimmune diseases such as diabetes, lupus, rheumatoid arthritis and multiple sclerosis. Terms of the transaction were not disclosed. 

Cancer research sector grows in Upstate 

CANCER RESEARCH SECTOR GROWS IN UPSTATE

By Liz Segrist
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Published Oct. 10, 2011

Cancer treatment and research is transforming and creating jobs in the Upstate.

Hospital systems have expanded their cancer programs and research, while biotech companies and firms have relocated or expanded in the Upstate in recent years. Hiring has been on an upward trend with these companies as new technologies, therapies and vaccines are being created to fight cancer.

Glucotec Completes Capital Raise totaling $8.27 million

Published Sept. 20, 2011 by GSA Business

GlucoTec Inc., the privately held parent company of Glytec LLC, announced Monday the completion of Series A Preferred Stock financing totaling $8.27 million.

The financing was led by Sea Dragon Healthcare Partners, L.P., with participation by Standard Pacific Capital Holdings LLLP. Glytec will use the capital primarily to expand its direct U.S. sales force, increase its international presence and advance research and development.

Lab21 Acquires Myconostica;